PD-L2 / TCR activator - CHO Recombinant Cell Line
Catalog #
79632
$9,400
*
●
●
Purchase
Description
Recombinant CHO-K1 cells constitutively expressing human PD-L2 (Programmed Cell Death 1 Ligand 2 or CD273, GenBank accession #NM_025239) and an engineered T-cell receptor (TCR) activator.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
●
Synonyms
Programmed Cell Death 2 Ligand 2, PDL2, PD-L2, CD273, PDCDL1G2, B7-DC
●
Product Data Gallery
Product Info
Storage and Usage
Citations
Host Cell Line
CHO-K1
Species
Human
Materials Required But Not Supplied
- PD-1/NFAT reporter Jurkat cell line (BPS Bioscience #60535)
- Assay medium: Thaw Medium 2 (BPS Bioscience #60184):
(RPMI1640 + 10% FBS + 1% Penicillin/Streptomycin) - Growth Medium 3A (BPS Bioscience #60188)
- Anti-PD-1 neutralizing antibody (BPS Bioscience #71120)
- 96-well tissue culture-treated white clear-bottom assay plate
- One-Step luciferase assay system (BPS Bioscience #60690)
- Luminometer
- Thaw Medium 3 (BPS Bioscience #60186):
Ham’s F-12 medium (Hyclone #SH30526.01) supplemented with 10% FBS (Life technologies #26140-079) and 1% Penicillin/Streptomycin (Hyclone SV30010.01)
UniProt #
Q9BQ51
Mycoplasma Testing
The cell line has been screened using the PCR-based Venor®GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of Mycoplasma species.
Background
The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes.